Arthrosurface said yesterday it won FDA 510(k) clearance for its OVOMotion shoulder arthroplasty system.
The Franklin, Mass.-based company said the newly cleared stemless total shoulder system is designed to minimize bone removal specifically for patients with painful or severely disabled shoulder joints from arthritis, traumatic events or avascular necrosis.
“This truly is a revolutionary stemless total shoulder, which combines the concept of anatomic restoration with an aspherical head design that more closely replicates patient anatomy but also allows improved joint access for ease of preparation of the glenoid,” Dr.Anthony Miniaci said in a prepared statement.
The OVOMotion shoulder system is now cleared for use in conjunction with the company’s novel inlay glenoid system, Arthrosurface said. The company touted that a comparative study of the inlay glenoid design showed that it was superior to onlay alternatives in respect to biomechanical stability.
“The OVOMotion shoulder arthroplasty system is intended to be the first of a three-element modular stemless system that will ultimately allow surgeons to intra-operatively choose between stemless, traditional and reverse options,” CEO Steve Ek said in a press release.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.